A home sleep test measures airflow, breathing effort, and oxygen levels while you sleep in your own bed — convenient and less expensive, but it only detects obstructive sleep apnea. An in-lab polysomnography monitors brain waves, heart rhythm, leg movements, and sleep stages in addition to breathing — it can diagnose central sleep apnea, narcolepsy, and other disorders. We recommend the appropriate test based on your symptoms.

In OSA, the airway collapses completely (apnea) or significantly (hypopnea), causing measurable oxygen desaturation. In UARS, the airway narrows enough to increase breathing effort and fragment sleep, but airflow reduction and oxygen drops do not meet apnea/hypopnea scoring thresholds. The symptoms can be equally severe, but UARS requires different diagnostic criteria (RDI rather than AHI) to detect.

Home sleep tests measure AHI (apneas and hypopneas) but do not detect RERAs (respiratory effort-related arousals), which define UARS. The AHI appears normal, leading clinicians to conclude that the patient does not have sleep-disordered breathing. Definitive UARS diagnosis requires in-laboratory polysomnography with effort sensors. Additionally, the typical UARS patient — younger, leaner, often female — does not fit the stereotypical sleep apnea profile, further delaying diagnosis.

Chronic fatigue and daytime sleepiness despite apparently adequate sleep duration, non-restorative sleep, morning headaches, difficulty concentrating, insomnia (especially difficulty maintaining sleep), cold hands and feet, low blood pressure, and irritability. Many patients have been evaluated for chronic fatigue syndrome, fibromyalgia, or depression before UARS is identified.

Yes. Mandibular advancement devices that increase pharyngeal airway dimensions are effective for UARS because the underlying mechanism is the same as mild OSA — partial airway narrowing that increases respiratory effort. By opening the airway, the oral appliance reduces the respiratory effort that triggers arousals, allowing sleep architecture to normalize. Many UARS patients report dramatic improvement with oral appliance therapy.

Definitive diagnosis requires in-laboratory polysomnography with respiratory effort monitoring (esophageal pressure manometry or respiratory inductance plethysmography). An improved Respiratory Disturbance Index (RDI) — which includes RERAs — in the setting of a normal or near-normal AHI is diagnostic. CBCT airway analysis at ADSC provides supporting anatomical evidence of airway narrowing consistent with UARS.

Yes. UARS was first described by Dr. Christian Guilleminault at Stanford Sleep Medicine in 1993. It is recognized in the International Classification of Sleep Disorders and has a substantial body of peer-reviewed research documenting its pathophysiology, diagnostic criteria, and treatment outcomes. It remains underdiagnosed primarily because of limitations in standard home sleep testing methodology.

UARS causes chronic sleep fragmentation, which produces functional impairment (fatigue, cognitive decline, mood disturbance) comparable to mild OSA. The cardiovascular risk profile of UARS is less well-studied than OSA, but the chronic sympathetic activation from frequent arousals is biologically consistent with increased cardiovascular strain. Some researchers consider UARS a precursor to OSA that progresses over time as tissue compliance decreases with aging.

Yes. Children with narrow palates, enlarged tonsils, and retrognathic mandibles can have UARS — presenting with behavioral problems, inattention, restless sleep, and fatigue rather than the classic adult symptoms. Pediatric UARS is often misdiagnosed as ADHD. The pediatric airway assessment at ADSC screens for structural contributors to respiratory effort-related sleep disturbance.

CBCT airway analysis measures the cross-sectional area and volume of the pharyngeal airway. Patients with UARS typically show airway narrowing (minimum cross-sectional area below 50-60 mm2) at the retropalatal or retroglossal level — anatomical evidence that supports the clinical diagnosis and guides treatment planning for oral appliance therapy or surgical intervention.

Custom mandibular advancement devices, CPAP at low pressure settings, positional therapy, nasal breathing optimization, myofunctional therapy, and in selected cases, maxillomandibular advancement surgery. The choice depends on severity, anatomy, and patient preference. Oral appliance therapy is the most common initial treatment due to its efficacy and tolerability for the relatively mild airway obstruction characteristic of UARS.

Nasal obstruction is a significant contributing factor in many UARS patients. Increased nasal resistance forces mouth breathing, which alters tongue posture and pharyngeal dynamics during sleep. Treating nasal obstruction (allergic rhinitis management, nasal surgery for deviated septum or turbinate hypertrophy) can reduce respiratory effort and improve UARS symptoms, often as an adjunct to oral appliance therapy.

If your home sleep test showed a normal AHI but you have persistent fatigue, non-restorative sleep, morning headaches, and difficulty concentrating, UARS should be considered. A clinical evaluation at ADSC — including CBCT airway analysis and review of your sleep study data — can determine whether anatomical airway narrowing supports this diagnosis and whether a trial of oral appliance therapy is warranted.

Unlike OSA, which strongly correlates with obesity, UARS frequently affects lean, young patients — particularly women. The primary contributing factors are craniofacial anatomy (small jaw, narrow palate) rather than body mass. Weight management is less impactful for UARS than for OSA, though overall health benefits still apply.

Some researchers consider UARS a point on the sleep-disordered breathing continuum that can progress to OSA as the pharyngeal tissues lose compliance with aging, weight gain accumulates, and muscle tone decreases. Early treatment of UARS may prevent this progression by maintaining airway patency and establishing proper breathing patterns, though definitive longitudinal data is still accumulating.